PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab in the second-line treatment of patients with unknown primary tumors.
Cancer of Unknown Primary
DRUG: Recombinant humanized anti-PD-1 monoclonal antibody injection
objective response rate (ORR) was assessed using RECIST1.1 and IRECIST standards., ORR is defined as CR+PR, Approximately 24 months
Recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab treatment, once every 3 weeks, treatment until disease progression, intolerable adverse reactions, patient death or withdrawal informed agree.After treatment, the patients was followed up every 9 weeks for follow-up treatment and survival.